Pan-KRAS inhibitor compound
By forming a ternary complex with Cyclophilin A, the downstream signaling pathway of KRAS is blocked, and the problem of lack of effective inhibitors for mutations in other sites of KRAS in the prior art is solved, effective inhibition of KRAS is achieved, and new Tumor treatment plan.
Patent Information
- Application Number
- CN202411157539.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-12-19
- Filing Date
- 2023-11-15
- Publication Date
- 2024-11-22
AI Technical Summary
It is difficult to develop effective pan-KRAS inhibitors, especially mutations targeting other sites of KRAS, resulting in KRAS being considered an inotropic target, lacking satisfactory inhibitors, and clinical needs are not fully met.
The compounds that play a role by forming a ternary complex with chaperone proteins such as Cyclophilin A, blocking the binding of KRAS to its downstream effector molecules, inhibiting the MAPK and PI3K-AKT signaling pathways.
Effectively inhibiting the activity of KRAS, blocking tumor occurrence and development, providing new possibilities for treating diseases such as tumors, and filling the gap in the prior art.
Smart Images

Figure CN118994202A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a compound, in particular to a highly active pan-KRAS inhibitor and use thereof. Background Art
[0002] RAS is one of the most commonly mutated genes in human tumors, with mutations occurring in about 30% of tumor patients, of which KRAS accounts for about 85% of RAS mutations. KRAS mutations are present in 88% of pancreatic cancers, 50% of colorectal adenocarcinomas, and 32% of lung adenocarcinomas. The development of inhibitors targeting KRAS has great clinical significance and value.
[0003] KRAS is a membrane-bound protein with GTPase activity. It cycles between the GDP-bound inactive conformation and the GTP-bound active conformation through nucleotide exchange, performing the function of a "molecular switch". KRAS in the GTP-bound state can activate multiple downstream signaling pathways including RAF-MEK-ERK and PI3K-AKT, regulating life processes such as cell growth, proliferation, differentiation and apoptosis.
[0004] KRAS mutations (such as G12C, G12D, G12V, G13D, etc.) affect GTPase-activating proteins (GAPs)-mediated GTP hydrolysis, increasing KRAS in the GTP-bound activated state, overactivating downstream signaling pathways, and ultimately leading to the occurrence and development of tumors. However, since the KRAS protein lacks a corresponding hydrophobic pocket suitable for drug binding, and its affinity for GTP and GDP is at the picomolar level (~20pM), the development of inhibitors that competitively bind to KRAS is very difficult. In the past few decades, KRAS has been considered an undruggable target.
[0005] In May 2021, AMG510 was approved by the FDA for the treatment of KRAS G12C Mutation of locally advanced or metastatic non-small cell lung cancer has broken the history of KRAS being "undruggable". However, G12C mutations only account for a small part of KRAS mutations. For mutations at other sites of KRAS, there is currently a lack of satisfactory and effective inhibitor compounds, and there are a large number of clinical needs that have not yet been met. Therefore, the development of effective pan-KRAS inhibitor compounds is a need in the existing technology. Summary of the invention
[0006] The present invention provides a pan-KRAS inhibitor. This structure is different from the existing KRAS inhibitors that work by covalent binding. G12CInstead of being an inhibitor, it works by mediating the formation of a ternary complex between the ubiquitous chaperone proteins (such as Cyclophilin A) in the cell and the KRAS protein. The formation of the ternary complex can block the binding of KRAS and its downstream effector molecules (such as RAF) through steric hindrance, inhibit the activation of MAPK and PI3K-AKT signaling pathways, and thus inhibit the occurrence and development of tumors, playing a role in treating tumors and other diseases.
[0007] In one aspect, the present invention provides a compound having the following structure:
[0008]
[0009] In a preferred embodiment of the present invention, the compound 1 is prepared by the following steps:
[0010]
[0011] Step 1: Dissolve the intermediates INT-2 and INT-6 in a mixed solvent of 1,4-dioxane and water, add [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium and potassium phosphate; replace nitrogen in the reaction system and heat to 70°C and stir for 12 hours; wait for the reaction solution to cool to room temperature, filter the reaction solution with diatomaceous earth, and concentrate the filtrate. The residue is purified by preparative thin layer chromatography (dichloromethane / methanol=30 / 1) to obtain compound 1a;
[0012] Step 2: Compound 1a was dissolved in N,N-dimethylformamide, cesium carbonate was added, and then iodoethane was added dropwise to the reaction solution, and the reaction solution was stirred at room temperature for 6 hours; LCMS detected that the reaction was complete; saturated brine was added to the reaction system, extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated to obtain compound 1b;
[0013] Step 3: The crude product of the above compound 1b was dissolved in dichloromethane, and trifluoroacetic acid was added dropwise to the reaction solution at 0°C; the reaction was continued to be stirred at 0°C for 1 hour; LCMS detected the completion of the reaction; the reaction solution was quenched with a saturated sodium bicarbonate aqueous solution, extracted with dichloromethane, separated, and the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated to obtain compound 1c;
[0014] Step 4: Dissolve the above compound 1c and intermediate INT-3 in N,N-dimethylformamide, add N,N-diisopropylethylamine and (2-oxime-cyanoacetic acid ethyl)-N,N-dimethyl-morpholinoura hexafluorophosphate, and stir the reaction solution at 0°C for 30 minutes; LCMS detection shows that the reaction is complete; add saturated brine to the reaction system, extract with ethyl acetate, combine the organic phases, wash with saturated brine, dry over anhydrous sodium sulfate, filter and concentrate, and purify the residue by preparative liquid chromatography to obtain white solid compound 1 and diastereoisomer compound 1'.
[0015] In one aspect, the present invention also provides a pharmaceutical composition comprising any of the aforementioned compounds or pharmaceutically acceptable salts, isotopic derivatives, and stereoisomers thereof.
[0016] In one aspect, the present invention also provides the use of the aforementioned compounds or their pharmaceutically acceptable salts, isotopic derivatives, stereoisomers and pharmaceutical compositions in the preparation of drugs for preventing and / or treating cancer, tumors, inflammatory diseases, autoimmune diseases or immune-mediated diseases.
[0017] In one aspect, the present invention also provides a method for preventing and / or treating cancer, tumors, inflammatory diseases, autoimmune diseases or immune-mediated diseases, comprising administering to a patient in need thereof a therapeutically effective amount of a compound as described above or a pharmaceutically acceptable salt, isotope derivative, stereoisomer and / or pharmaceutical composition thereof. It should be noted that, in this article, when referring to the "compound" of the structure of formula (I) or formula (II), it generally also covers its stereoisomers, diastereomers, enantiomers, racemic mixtures and isotope derivatives.
[0018] It is well known to those skilled in the art that a salt, solvate, or hydrate of a compound is an alternative form of the compound, and they can all be converted into the compound under certain conditions. Therefore, it should be noted that when referring to compounds of formula (I) or (II) herein, they generally also include their pharmaceutically acceptable salts, and further include their solvates and hydrates.
[0019] Similarly, when a compound is referred to herein, prodrugs, metabolites, and N-oxides thereof are also generally included.
[0020] The "stereoisomerism" described in the present invention is divided into conformational isomerism and configurational isomerism. Configurational isomerism can also be divided into cis-trans isomerism and optical isomerism (i.e. optical isomerism). Conformational isomerism refers to a stereoisomerism phenomenon in which the atoms or atomic groups of molecules have different arrangements in space due to the rotation or distortion of carbon and carbon single bonds in organic molecules with a certain configuration. Common structures include the structures of alkane and cycloalkane compounds, such as the chair conformation and boat conformation that appear in the structure of cyclohexane. "Stereoisomer" refers to when the compounds of the present invention contain one or more asymmetric centers, and thus can be used as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and single diastereoisomers. The compounds of the present invention have asymmetric centers, and each asymmetric center will produce two optical isomers. The scope of the present invention includes all possible optical isomers and diastereomeric mixtures and pure or partially pure compounds. The compounds described in the present invention can exist in the form of tautomers, which have different hydrogen connection points due to one or more double bond displacements. For example, a ketone and its enol form are keto-enol tautomers. Each tautomer and mixtures thereof are included in the compounds of the present invention. Enantiomers, diastereomers, racemates, mesomorphs, cis-trans isomers, tautomers, geometric isomers, epimers and mixtures thereof of all formula (I) to formula (III) compounds are included in the scope of the present invention.
[0021] The "isotopic derivative" of the present invention refers to a molecule in which the compound is isotopically labeled. The isotopes commonly used as isotopic labels are: hydrogen isotopes, 2 H and 3 H; Carbon isotope: 11 C, 13 C and 14 C; Chlorine isotope: 35 Cl and 37 Cl; Fluorine isotope: 18 F; Iodine isotope: 123 I and 125 I; Nitrogen isotopes: 13 N and 15 N; oxygen isotope: 15 O, 17 O and 18 O and sulfur isotopes 35 S. These isotope-labeled compounds can be used to study the distribution of drug molecules in tissues. 3 H and carbon 13 C, because they are easy to label and detect, they are more widely used. Some heavy isotopes, such as deuterium ( 2H), the substitution can enhance metabolic stability, prolong half-life and thus achieve the purpose of reducing dosage and provide therapeutic advantages. Isotope-labeled compounds are generally synthesized from labeled starting materials using known synthesis techniques in the same way as non-isotope-labeled compounds.
[0022] The present invention also provides the use of the compound of the present invention in preparing a medicament for preventing and / or treating cancer, tumor, inflammatory disease, autoimmune disease or immune-mediated disease.
[0023] In addition, the present invention provides a pharmaceutical composition for preventing and / or treating cancer, tumors, inflammatory diseases, autoimmune diseases, neurodegenerative diseases, attention-related diseases or immune-mediated diseases, which comprises the compound of the present invention as an active ingredient. The pharmaceutical composition may optionally comprise a pharmaceutically acceptable carrier.
[0024] In addition, the present invention provides a method for preventing and / or treating cancer, tumors, inflammatory diseases, autoimmune diseases, neurodegenerative diseases, attention-related diseases or immune-mediated diseases, which comprises administering a compound of the present invention to a mammal in need thereof.
[0025] When the compound of the present invention or a pharmaceutically acceptable salt thereof is administered in combination with another anticancer agent or immune checkpoint inhibitor for treating cancer or tumor, the compound of the present invention or a pharmaceutically acceptable salt thereof may provide an enhanced anticancer effect.
[0026] When the compounds of the present invention or their pharmaceutically acceptable salts are administered in combination with another therapeutic agent for treating inflammatory diseases, autoimmune diseases and immune-mediated diseases, the compounds of the present invention or their pharmaceutically acceptable salts may provide enhanced therapeutic effects.
[0027] The pharmaceutical composition of the present invention can be formulated into dosage forms for oral administration or parenteral administration (including intramuscular, intravenous and subcutaneous routes, intratumor injection) according to any of the conventional methods, such as tablets, granules, powders, capsules, syrups, emulsions, microemulsions, solutions or suspensions.
[0028] Other features of the invention will become apparent as the present invention proceeds through the description of exemplary embodiments, which are given to illustrate the invention and are not intended to be limiting thereof. The following examples were prepared, isolated, and characterized using the methods disclosed herein.
[0029] The compounds of the present invention can be prepared in a variety of ways known to those skilled in the art of organic synthesis, and the compounds of the present invention can be synthesized using the following methods and synthetic methods known in the field of organic synthetic chemistry or by variations thereof known to those skilled in the art. Preferred methods include, but are not limited to, those described below. The reaction is carried out in a solvent or solvent mixture suitable for the kit materials used and suitable for the transformation achieved. It will be understood by those skilled in the art of organic synthesis that the functionality present on the molecule is consistent with the proposed transformation. This sometimes requires judgment to change the order of the synthesis steps or the raw materials to obtain the desired compounds of the present invention. DETAILED DESCRIPTION
[0030] the term
[0031] Unless otherwise stated, the terms used in this application, including the specification and claims, are defined as follows. Unless otherwise stated, conventional methods of mass spectrometry, nuclear magnetic resonance, HPLC, protein chemistry, biochemistry, recombinant DNA technology and pharmacology are used. In this application, if not otherwise stated, the use of "or" or "and" means "and / or".
[0032] In the specification and claims, a given chemical formula or name shall encompass all stereoisomers and optical isomers thereof and racemates in which such isomers exist. Unless otherwise indicated, all chiral (enantiomers and diastereomers) and racemic forms are within the scope of the present invention. Multiple geometric isomers of C=C double bonds, C=N double bonds, ring systems, etc. may also exist in the compounds, and all such stable isomers are encompassed by the present invention. The present invention describes cis- and trans- (or E- and Z-) geometric isomers of the compounds of the present invention, and they can be separated into mixtures of isomers or separated isomeric forms. The compounds of the present invention can be separated in optically active or racemic form. All methods for preparing the compounds of the present invention and the intermediates prepared therein are considered to be part of the present invention. When enantiomeric or diastereomeric products are prepared, they can be separated by conventional methods (e.g., by chromatography or fractional crystallization). Depending on the process conditions, the final product of the present invention is obtained in free (neutral) or salt form. Both the free forms and salts of these end products are within the scope of the present invention. If desired, one form of the compound may be converted into another form. A free base or acid may be converted into a salt; a salt may be converted into a free compound or another salt; a mixture of isomeric compounds of the present invention may be separated into individual isomers. The compounds of the present invention, their free forms and salts may exist in a variety of tautomeric forms, in which hydrogen atoms are transposed to other parts of the molecule and the chemical bonds between the atoms of the molecule are rearranged. It should be understood that all tautomeric forms that may exist are included in the present invention.
[0033] The term "effective amount" as used herein means the amount of a drug or medicament (i.e., a compound of the present invention) that will cause a biological or medical response of a tissue, system, animal, or human being, such as that sought by a researcher or clinician. In addition, the term "therapeutically effective amount" means an amount that results in improved treatment, cure, prevention, or alleviation of a disease, condition, or side effect, or reduces the rate of progression of a disease or condition, compared to a corresponding subject that has not received the above amount. An effective amount can be given in one or more administrations, applications, or doses and is not intended to be limited by a specific formulation or route of administration. The term also includes an effective amount that enhances normal physiological function within its scope.
[0034] As used herein, the term "treat," ...
[0035] The term "pharmaceutically acceptable" is used herein to refer to those compounds, substances, compositions and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and animals without excessive toxicity, irritation, allergic response and / or other problems or complications, and commensurate with a reasonable benefit / risk ratio.
[0036] As used herein, the phrase "pharmaceutically acceptable carrier" means a pharmaceutical substance, composition or vehicle, such as a liquid or solid filler, diluent, excipient, manufacturing aid (e.g., lubricant, talc, magnesium, calcium or zinc stearate or stearic acid) or solvent encapsulating substance, which is involved in carrying or transporting the subject compound from one organ or part of the body to another. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.
[0037] The term "pharmaceutical composition" means a composition comprising a compound of the present invention and at least one other pharmaceutically acceptable carrier. "Pharmaceutically acceptable carrier" refers to a medium generally accepted in the art for delivering a biologically active agent to an animal (particularly a mammal), including (i.e.) adjuvants, excipients or vehicles, such as diluents, preservatives, fillers, flow regulators, disintegrants, wetting agents, emulsifiers, suspending agents, sweeteners, flavoring agents, aromatics, antibacterial agents, antifungal agents, lubricants and dispersants, depending on the nature of the mode of administration and dosage form.
[0038] The term "acceptable," as used herein, means that a formulation component or active ingredient has no undue deleterious effect on health and well-being for the general purpose of treatment.
[0039] The term "cancer", as used herein, refers to an abnormal growth of cells that cannot be controlled and can metastasize (spread) under certain conditions. This type of cancer includes, but is not limited to, solid tumors (such as bladder, intestine, brain, chest, uterus, heart, kidney, lung, lymphoid tissue (lymphoma), ovary, pancreas or other endocrine organs (such as thyroid), prostate, skin (melanoma) or blood tumors (such as non-leukemic leukemia).
[0040] The term "combination administration" or its like, as used herein, refers to the administration of several selected therapeutic agents to one patient, in the same or different administration routes and at the same or different times.
[0041] The term "enhance" or "enhancing", as used herein, refers to the ability to increase or prolong the effectiveness or duration of a desired result. Therefore, in terms of enhancing the therapeutic effect of a drug, the term "enhancing" refers to the ability of a drug to increase or prolong the effectiveness or duration in a system. "Efficacy value" as used herein refers to the ability to maximize the enhancement of another therapeutic drug in an ideal system.
[0042] The term "immune disease" refers to a disease or condition that is caused by an adverse or harmful response to endogenous or exogenous antigens. The result is usually cellular dysfunction, or the resulting damage and malfunction of, or destruction of, organs or tissues that may produce immune symptoms.
[0043] The terms "kit" and "product package" are synonymous.
[0044] The term "subject" or "patient" includes mammals and non-mammals. Mammals include, but are not limited to, mammals: humans, non-human primates such as gorillas, apes and monkeys; agricultural animals such as cattle, horses, goats, sheep, pigs; livestock such as rabbits and dogs; experimental animals include rodents such as rats, mice and guinea pigs. Non-mammalian animals include, but are not limited to, birds, fish, etc. In a preferred aspect, the selected mammal is a human.
[0045] The terms "treat," "treatment," or "therapy" as used herein include alleviating, inhibiting, or ameliorating symptoms or conditions of a disease; inhibiting the development of complications; ameliorating or preventing underlying metabolic syndrome; inhibiting the development of a disease or symptom, such as controlling the progression of a disease or condition; alleviating a disease or symptom; causing a disease or symptom to regress; alleviating complications caused by a disease or symptom, or preventing and / or treating signs caused by a disease or symptom.
[0046] As used herein, a compound or pharmaceutical composition, after administration, can improve a disease, symptom or condition, especially improve its severity, delay the onset, slow the progression of the disease, or reduce the duration of the disease. Whether fixed or temporary administration, continuous or intermittent administration, can be attributed to or related to the administration.
[0047] Suitable routes of administration include, but are not limited to, oral, intravenous, rectal, aerosol, parenteral, ocular, pulmonary, transdermal, vaginal, auricular, nasal, and topical administration. In addition, parenteral administration, by way of example only, includes intramuscular, subcutaneous, intravenous, intramedullary, ventricular, intraperitoneal, intralymphatic, and intranasal injections.
[0048] On the one hand, the administration of the compounds described herein is local rather than systemic. In a specific embodiment, the long-acting formulation is administered by implantation (e.g., subcutaneous or intramuscular) or by intramuscular injection. In addition, in another embodiment, the drug is administered by a targeted drug delivery system. For example, a liposome wrapped by an organ-specific antibody. In this embodiment, the liposome is selectively directed to a specific organ and absorbed.
[0049] Drug composition and dosage
[0050] The present invention also provides a pharmaceutical composition comprising a therapeutically effective amount of one or more compounds of the present invention formulated with one or more pharmaceutical carriers (additives) and / or diluents, and optionally one or more other therapeutic agents described above. The compounds of the present invention can be administered in any suitable manner for any of the above uses, for example, orally, such as tablets, pills, powders, granules, elixirs, tinctures, suspensions (including nanosuspensions, microsuspensions, spray-dried dispersions), syrups and emulsions; sublingually; buccally; parenterally, such as by subcutaneous, intravenous, intramuscular or intrasternal injection or infusion techniques (e.g., in the form of sterile injectable aqueous or non-aqueous solutions or suspensions); nasally, including administration to the nasal membrane, such as by inhalation spray; topically, such as in the form of creams or ointments; or rectally, such as in the form of suppositories; or by intratumoral injection. They can be administered alone, but are usually administered using a pharmaceutical carrier selected based on the selected route of administration and standard pharmaceutical practice.
[0051] Pharmaceutical carriers include aqueous and non-aqueous liquid media and various solid and semi-solid pharmaceutical carriers. The above carriers may include many different ingredients and additives in addition to the active agent, and the above other ingredients are included in the formulation for various reasons known to those skilled in the art, such as stabilizers, binders, etc. Descriptions of suitable pharmaceutical carriers and factors involved in carrier selection can be found in a number of readily available sources, such as Allen LV Jr. et al. Remington: The Science and Practice of Pharmacy. 1 (2Volumes),22nd Edition(2012),PharmaceuticalPress.
[0052] The compound is usually administered in a mixture with a suitable pharmaceutical diluent, excipient or carrier (collectively referred to herein as a pharmaceutical carrier) appropriately selected according to the intended administration form (eg, oral tablets, capsules, elixirs and syrups) and in accordance with conventional pharmaceutical practice.
[0053] Dosage forms (pharmaceutical compositions) suitable for administration may contain from about 1 mg to about 2000 mg of active ingredient per dosage unit. In these pharmaceutical compositions, the active ingredient will generally be present in an amount of about 0.1-95% by weight based on the total weight of the composition.
[0054] The scope of the present invention includes (alone or in combination with a pharmaceutical carrier) a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of the present invention as an active ingredient. Optionally, the compound of the present invention can be used alone, in combination with other compounds of the present invention, or in combination with one or more other therapeutic agents (e.g., anticancer agents or other pharmaceutically active substances).
[0055] Regardless of the selected administration route, the compound of the present invention (which may be used in a suitable hydrated form) and / or the pharmaceutical composition of the present invention are formulated into a pharmaceutical dosage form by conventional methods known to those skilled in the art.
[0056] Actual dosage levels of the active ingredients in the pharmaceutical compositions of the present invention may be varied so as to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
[0057] The selected dosage level will depend upon a variety of factors, including the activity of the specific compound of the present invention being employed, or its ester, salt or amide; the route of administration; the time of administration; the rate of excretion of the specific compound being employed; the rate and extent of absorption; the duration of the treatment; other drugs, compounds and / or substances used in combination with the specific compound being employed; and the age, sex, weight, condition, general health and prior medical history of the patient being treated and other factors well known in the medical art.
[0058] The above features mentioned in the present invention or the features mentioned in the embodiments can be combined in any way. All the features disclosed in the specification of this case can be used in any combination form, and each feature disclosed in the specification can be replaced by any alternative feature that can provide the same, equivalent or similar purpose. Therefore, unless otherwise specified, the disclosed features are only general examples of equivalent or similar features.
[0059] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended only to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples without specifying specific conditions are usually performed under normal conditions or according to the conditions recommended by the manufacturer. Unless otherwise stated, all percentages, ratios, proportions, or parts are by weight.
[0060] The units of weight volume percentage in the present invention are well known to those skilled in the art, for example, refer to the weight (g) of solute in 100 ml of solution. Unless otherwise defined, all professional and scientific terms used in the text have the same meanings as those familiar to those skilled in the art. In addition, any methods and materials similar or equivalent to the described contents can be applied to the method of the present invention. The preferred implementation methods and materials described in the text are for demonstration purposes only.
[0061] Example
[0062] General process
[0063] When the preparation route is not included, the raw materials and reagents used in the present invention are all known products, which can be synthesized according to methods known in the art, or can be obtained by purchasing commercial products. The commercial reagents used do not need to be further purified.
[0064] Room temperature refers to 20-30°C.
[0065] Unless otherwise specified in the reaction examples, the reactions were carried out under a nitrogen atmosphere, which means that the reaction flask was connected to a nitrogen balloon of about 1 L.
[0066] The hydrogenation reaction is usually carried out by evacuating the vacuum and filling with hydrogen, and the operation is repeated three times. The hydrogen atmosphere means that the reaction bottle is connected to a hydrogen balloon of about 1L.
[0067] Microwave reaction use Initiator + microwave reactor.
[0068] The structures of the compounds of the present invention were determined by nuclear magnetic resonance (NMR) and mass spectrometry (MS). -6 The units of (ppm) are given. NMR measurements were performed using (Bruker Ascend TM500) NMR, the solvents used for the determination were deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl 3 ), deuterated methanol (CD 3 OD), with tetramethylsilane (TMS) as the internal standard. The following abbreviations are used for the multiplicity of NMR signals: s = singlet, brs = broad, d = doublet, t = triplet, m = multiplet. Coupling constants are listed as J values, measured in Hz.
[0069] The reverse phase preparative chromatography was performed using a Thermo (UltiMate 3000) reverse phase preparative chromatograph. The rapid column chromatography was performed using an Agilent (FS-9200T) automatic column machine, and the silica gel prepacked column was performed using a Santai Pre-packed column. Thin layer chromatography silica gel plate uses Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate, and the specification used for thin layer chromatography separation and purification products is 0.4mm~0.5mm.
[0070] The LC-MS analysis method is as follows:
[0071] 1) Mass spectrometry method: Thermo Fisher MSQ PLUS mass spectrometer, ESI source, positive ion mode. Ion source parameter settings: drying gas temperature 350°C; drying gas flow rate 10 L / min; MS Range: 120-1000.
[0072] 2) Liquid phase conditions: Chromatographic column: Waters XBridge (3.5 μm, 50 mm×4.6 mm); mobile phase A was an aqueous solution containing 0.1% ammonium bicarbonate, mobile phase B was an acetonitrile solution, and linear gradient elution was performed according to Table 1 below; flow rate: 2 mL / min; column temperature: 30°C; UV detection wavelengths: 214 nm, 254 nm, 280 nm; injection volume 2 μL.
[0073] Table 1. Gradient elution conditions
[0074]
[0075] The HPLC analysis method is as follows:
[0076] Chromatographic column: Waters XBridge phenyl (3.5 μm, 150 mm × 4.6 mm); mobile phase A was an aqueous solution containing 0.1% ammonium bicarbonate, mobile phase B was an acetonitrile solution, and linear gradient elution was performed according to Table 2; flow rate: 1 mL / min; column temperature: 30°C; UV detection wavelengths: 214 nm, 254 nm, 280 nm; injection volume 2 μL.
[0077] Table 2. Gradient elution conditions
[0078]
[0079] The synthesis methods of some intermediates in the invention are as follows:
[0080] Intermediate 1
[0081]
[0082] Intermediate 1 was prepared by the following steps:
[0083]
[0084] Step 1: Dissolve 2,2-dimethyl-3-hydroxypropionic acid methyl ester INT-1a (100g, 756.7mmol) in 1L N, N-dimethylformamide, add imidazole (128.8g, 1.89mol), stir to dissolve, add tert-butyldiphenylsilyl chloride (228.8g, 832.3mmol) dropwise at room temperature, continue stirring for 4 hours. After the reaction is complete, pour the reaction solution into 3L ice water, extract the suspension with ethyl acetate (1L*2), wash the organic phase with water 3 times, and concentrate under reduced pressure to obtain a colorless oil INT-1b, which is directly used in the next step without purification. ESI-MS (m / z): 371.2 [M+H] + .
[0085] Step 2: Add the residual liquid INT-1b obtained in the previous step to 2L methanol, add 360g of the prepared 33% sodium hydroxide aqueous solution, and stir at room temperature for 17 hours. After the reaction is completed, add 1L of water, remove the methanol under reduced pressure, extract the residual liquid with petroleum ether (1L*5), adjust the pH value of the aqueous phase to 4-5 with hydrochloric acid after extraction, continue stirring for 30 minutes, filter, and dry to obtain a white solid INT-1c (269g, yield 90%). ESI-MS (m / z): 357.8 [M+H] + .
[0086] Step 3: Dissolve INT-1c (130 g, 364.6 mmol) in 500 mL of dichloromethane, add thionyl chloride (130.1 g, 1.09 mol, 79.4 mL) at room temperature, stir at 60 ° C for 3 hours, and after the reaction is completed, remove the dichloromethane and the remaining thionyl chloride under reduced pressure to obtain a light yellow oil INT-1d. Without purification, add 200 mL of dichloromethane for standby use.
[0087] Step 4: Dissolve INT-1e (64.8 g, 331 mmol) in 400 mL of dichloromethane, add 198 mL of diethylaluminum chloride solution (2M in hexanes) at 0 ° C, control the temperature not to exceed 5 ° C during the addition process, stir for 30 minutes after the addition is completed, and add the obtained dichloromethane solution of INT-1d to the reaction bottle. The temperature during the addition process is controlled not to exceed 10 ° C, and the addition is completed and continued to stir for 2 hours. After the reaction is completed, pour the reaction solution into 1L of ice water, stir for 30 minutes, and then concentrate under reduced pressure to remove dichloromethane. The residual liquid is extracted with ethyl acetate (1L*2), washed with water, and the organic phase is concentrated under reduced pressure to obtain a brown oil. The oil is added to a mixed solution of 2L of petroleum ether / ethyl acetate = 10 / 1, stirred to precipitate solids, and filtered to obtain a yellow solid INT-1f (139 g, yield 78%). ESI-MS (m / z): 534.8 [M+H] + .
[0088] Step 5: INT-1f (100 g, 187.1 mmol) was dissolved in 500 mL of tetrahydrofuran, lithium borohydride (12.2 g, 561.2 mmol) was added, and the mixture was stirred at 60 °C overnight. After the raw material disappeared, the reaction solution was added into 200 mL of ice water to quench, and extracted with ethyl acetate (500 mL*3). The organic phase was washed with water, dried, and concentrated under reduced pressure. The residual liquid was dissolved in 500 mL of dichloromethane, and 2,6-dimethyl-1,4- Dihydro-3,5-pyridinedicarboxylic acid diethyl ester (28.4 g, 112.2 mmol) and p-toluenesulfonic acid (21.4 g, 112.2 mmol) were stirred at room temperature for 3 hours. After the reaction was completed, the mixture was concentrated under reduced pressure to remove dichloromethane. The residual liquid was dissolved in 500 mL of methanol, and a pre-prepared 14% aqueous lithium hydroxide solution (100 mL) was added. The mixture was stirred at room temperature for 3 hours and filtered to obtain a yellow solid INT-1g (84 g, yield 86.3%). ESI-MS (m / z): 520.2 [M+H] + .
[0089] Step 6: Dissolve INT-1g (50g, 96mmol) in 250mL tetrahydrofuran, add tetrabutylammonium fluoride (1M inTHF, 197mL), stir overnight at 60°C, and after the reaction is completed, add the reaction solution into 300mL water, extract with ethyl acetate (200mL*3), wash with water, and concentrate under reduced pressure to obtain a brown oil. The obtained residue was dissolved in 40mL methanol, 20mL water was added, the mixed solution was washed with petroleum ether (40mL*5), concentrated under reduced pressure to remove methanol, and the residue was extracted with ethyl acetate (50mL*2), the organic phase was washed with water, and dried to obtain a light yellow oil INT-1h (25g, yield 90.4%). ESI-MS (m / z): 282.8 [M+H] + .
[0090] Step 7: Dissolve the compound INT-1h (22 g, 77 mmol) in 100 mL of dichloromethane. Add 4-dimethylaminopyridine (467 mg, 3.82 mmol) and triethylamine (23.2 g, 230 mmol), and dropwise add acetic anhydride (7.9 g, 77 mmol) at 0°C. After the addition is complete, the temperature is naturally raised and stirred overnight. When the reaction is complete, the reaction solution is washed with water, dried, and concentrated to obtain a brown oil. Purify by silica gel column chromatography (petroleum ether / ethyl acetate = 4 / 1) to obtain a light yellow oil INT-1i (22.5 g, yield 90.7%). ESI-MS (m / z): 324.2 [M+H] + .
[0091] Step 8: Dissolve compound INT-1i (40 g, 123.4 mmol) in dioxane (400 mL), add potassium acetate (30.3 g, 308.4 mmol), [1,1'-bis(diphenylphosphino)ferrocene] palladium dichloride (10 g, 12.3 mmol), and diboric acid pinacol ester (78.3 g, 308.4 mmol), react at 90 ° C for 3 hours under nitrogen protection, LCMS monitoring raw material reaction is complete, the reaction solution is directly concentrated under reduced pressure, the residue is dissolved in ethyl acetate (300 mL), washed with water, washed with brine, and the organic phase is purified by silica gel column chromatography to obtain a white solid compound INT-1j (35 g, yield 76.4%). ESI-MS (m / z): 372.5 [M+H] + .
[0092] Step 9: Compound INT-1j (35 g, 94.3 mmol) and compound INT-1k (37.9 g, 103.7 mmol) were dissolved in dioxane (300 mL) and water (30 mL), potassium phosphate (50 g, 235.7 mmol) and [1,1'-bis(diphenylphosphino)ferrocene] palladium dichloride (6.89 g, 9.43 mmol) were added, and the mixture was reacted at 90°C overnight under nitrogen protection. LCMS monitored that the raw material reaction was complete, and the reaction solution was directly concentrated under reduced pressure. The residue was dissolved in ethyl acetate (300 mL), washed with water and brine, and the organic phase was purified by silica gel column chromatography to obtain a yellow oily compound INT-1l (28 g, yield 56.08%). ESI-MS (m / z): 530.7 [M+H] + .
[0093] Step 10: Dissolve compound INT-11 (28 g, 52.9 mmol) in N,N-dimethylformamide (280 mL), add N-iodosuccinimide (11.9 g, 52.9 mmol), react at 50°C for 2 hours, monitor the reaction of the raw materials, pour the reaction solution into water (800 mL), extract with ethyl acetate (200 mL*2), wash the organic phase with saturated brine, dry, filter, and purify by silica gel column chromatography to obtain yellow solid compound INT-1m (22 g, yield 63.5%). ESI-MS (m / z): 656.6 [M+H] + .
[0094] Step 11: Dissolve compound INT-1m (5 g, 7.63 mmol), 2-dicyclohexylphosphine-2′,6′-dimethoxy-biphenyl (939.4 mg, 2.29 mmol), tris(dibenzylideneacetone)dipalladium (838.1 mg, 0.915 mmol), potassium acetate (2.6 g, 26.7 mmol) in toluene (100 mL), add pinacol borane (4.9 g, 38.1 mmol) under nitrogen protection, add dropwise, react at 50° C. under nitrogen protection for 5 hours, LCMS monitors the reaction of the raw materials, filter the reaction solution, and purify by silica gel column chromatography to obtain a yellow oily compound INT-1 (4.5 g, yield 90%). ESI-MS (m / z): 656.5 [M+H] + .
[0095] Intermediate 2
[0096]
[0097] Intermediate 2 was prepared by the following steps:
[0098]
[0099] Step 1: Dissolve compound INT-1m (12 g, 18.3 mmol) in tetrahydrofuran (120 mL) and water (20 mL), add lithium hydroxide monohydrate (3.84 g, 91.5 mmol), react at room temperature overnight, monitor the reaction of the raw materials, concentrate the reaction solution under reduced pressure, dissolve the residue in water (100 mL), adjust the pH to 4-5 with 4M hydrochloric acid, extract with dichloromethane (100 mL*3), wash the organic phase with water, wash with brine, dry with anhydrous sodium sulfate, filter, and concentrate to obtain a white solid compound INT-2a (10.6 g, yield 96.6%). ESI-MS (m / z): 600.7 [M+H] + .
[0100] Step 2: Dissolve compound INT-2a (9.5 g, 15.9 mmol) and compound INT-2b (11.7 g, 31.7 mmol) in acetonitrile (190 mL), add N,N,N',N'-tetramethylchloroformamidine hexafluorophosphate (6.67 g, 23.8 mmol) and 1-methylimidazole (6.51 g, 79.2 mmol) at 0°C, react at 0°C for 1 hour, LCMS monitors the complete reaction of the raw materials, pour the reaction solution into water (200 mL), extract with dichloromethane (100 mL*3), wash the organic phase with water, and purify by silica gel column chromatography to obtain yellow solid compound INT-2c (9.6 g, yield 83.5%). ESI-MS (m / z): 726.3 [M+H] + .
[0101] Step 3: Dissolve compound INT-2c (9.6 g, 13.2 mmol) in tetrahydrofuran (100 mL) and water (10 mL), add lithium hydroxide monohydrate (1.39 g, 33.1 mmol), react at room temperature for 4 hours, monitor the reaction of the raw materials, concentrate the reaction solution under reduced pressure, dissolve the residue in water (100 mL), adjust the pH to 4-5 with 4M hydrochloric acid, and a white solid precipitates. Filter, wash the solid with water, and dry to obtain a white solid compound INT-2d (8.3 g, yield 88.2%). ESI-MS (m / z): 712.6 [M+H] + .
[0102] Step 4: Dissolve compound INT-2d (3.5 g, 4.9 mmol), 1-hydroxybenzotriazole (1.99 g, 14.8 mmol), and 4-dimethylaminopyridine (1.8 g, 14. mmol) in dichloromethane (170 mL), add N, N-diisopropylethylamine (6 mL, 34.4 mmol) at 0°C, and then add 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (4.71 g, 24.6 mmol), react overnight at room temperature, and LCMS monitors that the raw materials react completely. The reaction solution is washed with saturated ammonium chloride aqueous solution, dried with sodium sulfate, and purified by silica gel column chromatography to obtain a yellow solid compound INT-2e (2 g, yield 58.6%). ESI-MS (m / z): 694.6 [M+H] + .
[0103] Step 5: Dissolve compound INT-2e (500 mg, 0.721 mmol), 2-dicyclohexylphosphine-2′,6′-dimethyl-biphenyl (88.8 mg, 0.216 mmol), tris(dibenzylideneacetone)dipalladium (79 mg, 0.086 mmol), potassium acetate (247 mg, 2.52 mmol) in tetrahydrofuran (20 mL), add pinacol borane (461 mg, 3.6 mmol) under nitrogen protection, add dropwise, react at 50° C. under nitrogen protection for 3 hours, LCMS monitors the complete reaction of the raw materials, filter the reaction solution, and purify by silica gel column chromatography to obtain a yellow solid compound INT-2 (400 mg, yield 80%). ESI-MS (m / z): 694.6 [M+H] + .
[0104] Intermediate 3
[0105]
[0106] Intermediate 3 was prepared by the following steps:
[0107]
[0108] Step 1: Dissolve compound INT-2e (1.7 g, 2.45 mmol) in dichloromethane (20 mL), add trifluoroacetic acid (5 mL), react at room temperature for 2 hours, and monitor the reaction of the raw material. The reaction solution is directly concentrated under reduced pressure, and the residue is dissolved in DCM (50 mL). Saturated NaHCO 3 The aqueous solution was washed twice, the organic phase was washed with water, dried with sodium sulfate, filtered, and concentrated to obtain a yellow solid compound INT-3a (1.3 g, yield 89.4%). ESI-MS (m / z): 594.7 [M+H] + .
[0109] Step 2: Dissolve compound INT-3a (1.3 g, 2.19 mmol) and compound INT-3b (0.24 g, 2.41 mmol) in acetonitrile (30 mL), add N,N,N',N'-tetramethylchloroformamidine hexafluorophosphate (921.9 mg, 3.29 mmol) and 1-methylimidazole (414 mg, 5.04 mmol) at 0°C, react at 0°C for 1 hour, LCMS monitors the complete reaction of the raw materials, pour the reaction solution into water (50 mL), extract with dichloromethane (50 mL*3), wash the organic phase with water, mix the sample and purify it through a column to obtain a white solid compound INT-3c (1.3 g, yield 87.9%). ESI-MS (m / z): 675.7 [M+H] + .
[0110] Step 3: Dissolve compound INT-3c (1.1 g, 1.63 mmol), 2-dicyclohexylphosphine-2′, 6′-dimethyl-biphenyl (200.5 mg, 0.188 mmol), tris(dibenzylideneacetone)dipalladium (179 mg, 0.195 mmol), potassium acetate (559 mg, 5.7 mmol) in toluene (30 mL), add pinacol borane (1.04 g, 8.14 mmol) under nitrogen protection, add dropwise, react at 50°C for 3 hours under nitrogen protection, LCMS monitors the reaction of the raw materials, filter the reaction solution, and purify by silica gel column chromatography to obtain yellow solid compound INT-3 (990 mg, yield 90%). ESI-MS (m / z): 676.9 [M+H] + .
[0111] Intermediate 4
[0112]
[0113] Intermediate 4 was prepared by the following steps:
[0114]
[0115] Step 1: Dissolve compound INT-3a (2.2 g, 3.71 mmol) and compound INT-4a (0.47 g, 4.08 mmol) in dichloromethane (50 mL), add N,N,N',N'-tetramethylchloroformamidine hexafluorophosphate (1.56 g, 5.56 mmol) and 1-methylimidazole (0.70 g, 8.53 mmol) at 0°C, react at 0°C for 1 hour, LCMS monitors the complete reaction of the raw materials, pour the reaction solution into water (50 mL), extract with dichloromethane (50 mL*3), wash the organic phase with water, mix the sample and purify it through a column to obtain a white solid compound INT-4b (2.3 g, yield 90.0%). ESI-MS (m / z): 690.2 [M+H] + .
[0116] Step 2: Dissolve compound INT-4b (2.1 g, 3.05 mmol), 2-dicyclohexylphosphine-2′,6′-dimethyl-biphenyl (375.0 mg, 0.91 mmol), tris(dibenzylideneacetone)dipalladium (334.6 mg, 0.365 mmol), potassium acetate (1.05 g, 10.7 mmol) in toluene (30 mL), add pinacol borane (1.95 g, 15.2 mmol) under nitrogen protection, add dropwise, react at 50°C for 3 hours under nitrogen protection, LCMS monitors the reaction of the raw materials, filter the reaction solution, and purify by silica gel column chromatography to obtain yellow solid compound INT-4 (1.8 g, yield 85.7%). ESI-MS (m / z): 690.3 [M+H] + .
[0117] Intermediate 5
[0118]
[0119] Intermediate 5 was prepared by the following steps:
[0120]
[0121] Step 1: Dissolve compound INT-5a (20 g, 58.5 mmol) and vinylboronic acid pinacol ester (10.8 g, 70.2 mmol) in 1,4-dioxane (120 mL) and water (12 mL), add potassium carbonate (16.2 g, 117.0 mmol), [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium (2.12 g, 2.92 mmol). 2 Stir overnight at 60°C under protective conditions. LCMS monitored that the raw material reacted completely. Distill under reduced pressure to remove excess solvent. Add the residue to water (100 mL), extract with ethyl acetate (100 mL*3), filter the organic phase, wash with water, and purify by column to obtain a white solid compound INT-5b (13 g, yield 92.0%). ESI-MS (m / z): 242.2 [M+H] + .
[0122] Step 2: Dissolve compound INT-5b (13 g, 53.69 mmol) in 300 mL of tetrahydrofuran, add 100 mL of water, stir, add sodium periodate (28.7 g, 134.2 mmol) and potassium osmate (157.50 mg, 536.9 umol), stir at 40°C for 3 hours, monitor the reaction of the raw materials by LCMS, separate the liquids, extract the aqueous phase with ethyl acetate (50 mL*3), combine the organic phases, wash with water, mix the sample and purify it by column to obtain a white solid compound INT-5c (11.2 g, yield 85.5%). ESI-MS (m / z): 244.5 [M+H] + .
[0123] Step 3: Dissolve compound INT-5c (1 g, 4.10 mmol) in 15 mL of ethanol and 10 mL of water, then add hydroxylamine hydrochloride (313.17 mg, 4.51 mmol) and sodium acetate (613.26 mg, 4.51 mmol), stir at room temperature for 1 hour, and monitor the reaction of the raw materials by LCMS. Filter and obtain a light yellow solid compound INT-5d (1.06 g, yield 94.2%). ESI-MS (m / z): 259.4 [M+H] + .
[0124] Step 4: Dissolve compound INT-5d (1.06 g, 3.86 mmol) in 15 mL tetrahydrofuran, add N-chlorosuccinimide (1.20 g, 9.01 mmol), stir at room temperature for 3 hours, monitor the reaction of the raw material by LCMS, add water (30 mL), extract with ethyl acetate (20 mL*3), and concentrate the organic phase to obtain a light yellow solid compound INT-5 (1.1 g, yield 85.8%). ESI-MS (m / z): 293.0 [M+H] + .
[0125] Intermediate 6
[0126]
[0127] Intermediate 6 was prepared by the following steps:
[0128]
[0129] Step 1: Dissolve the intermediate INT-5 (150 mg, 0.51 mmol) and the intermediate INT-6a (95 mg, 0.77 mmol) in a mixed solvent of dichloromethane (2 mL) and water (2 mL), and add sodium bicarbonate (129 mg, 1.53 mmol). The reaction solution was stirred at room temperature for 4 hours. LCMS detected that the reaction was complete. Add saturated brine to the reaction system, extract with dichloromethane, combine the organic phases, wash with saturated brine, dry with anhydrous sodium sulfate, filter and concentrate, and purify the residue with silica gel column chromatography (dichloromethane / methanol=10 / 1) to obtain a colorless oily liquid INT-6 (160 mg, yield 81%). ESI-MS (m / z): 382.7 [M+H] + .
[0130] The synthesis method of the embodiment compounds of the present invention is as follows:
[0131] Example 1
[0132]
[0133] Example 1 was prepared by the following steps:
[0134]
[0135] Step 1: Dissolve the intermediate INT-2 (109 mg, 0.16 mmol) and the intermediate INT-6 (50 mg, 0.13 mmol) in a mixed solvent of 1,4-dioxane (2 mL) and water (0.2 mL), and add [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (10 mg, 0.01 mmol) and potassium phosphate (83 mg, 0.39 mmol). After the reaction system was replaced with nitrogen, it was heated to 70 ° C and stirred for 12 hours. After the reaction solution was cooled to room temperature, the reaction solution was filtered with diatomaceous earth and the filtrate was concentrated. The residue was purified by preparative thin layer chromatography (dichloromethane / methanol = 30 / 1) to obtain compound 1a (103 mg, yield 90%). ESI-MS (m / z): 869.6 [M+H] + .
[0136] Step 2: Dissolve compound 1a (103 mg, 0.12 mmol) in N,N-dimethylformamide (2 mL), add cesium carbonate (77 mg, 0.24 mmol), then add iodoethane (37 mg, 0.24 mmol) dropwise to the reaction solution, and stir the reaction solution at room temperature for 6 hours. LCMS detection of the reaction is complete. Add saturated brine to the reaction system, extract with ethyl acetate, combine the organic phases, wash with saturated brine, dry with anhydrous sodium sulfate, filter and concentrate to obtain a crude product of compound 1b (106 mg, yield 100%). ESI-MS (m / z): 897.6 [M+H] + .
[0137] Step 3: Dissolve the crude product of the above compound 1b (106 mg, 0.12 mmol) in dichloromethane (1 mL), and add trifluoroacetic acid (67 mg, 0.59 mmol) dropwise to the reaction solution at 0°C. The reaction was continued to stir at 0°C for 1 hour. LCMS detected that the reaction was complete. The reaction solution was quenched with saturated sodium bicarbonate aqueous solution, extracted with dichloromethane, separated, and the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product of compound 1c (94 mg, yield 100%). ESI-MS (m / z): 797.6 [M+H] + .
[0138] Step 4: The crude product of the above compound 1c (94 mg, 0.12 mmol) and the intermediate INT-3 (24 mg, 0.24 mmol) were dissolved in N, N-dimethylformamide (3 mL), and N, N-diisopropylethylamine (46 mg, 0.35 mmol) and (2-oxime-cyanoacetic acid ethyl)-N, N-dimethyl-morpholinyl urea hexafluorophosphate (101 mg, 0.24 mmol) were added, and the reaction solution was stirred at 0 ° C for 30 minutes. LCMS detected that the reaction was complete. Saturated brine was added to the reaction system, extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was purified by preparative liquid chromatography to obtain white solid compound 1 (12 mg, yield 12%) and diastereomer compound 1' (15 mg, yield 15%). The absolute configurations of the two compounds are drawn based on the empirical assumption that compound 1 is the isomer with a longer retention time in LCMS or HPLC, while 1' is the isomer with a shorter retention time in LCMS or HPLC.
[0139] Compound 1
[0140] ESI-MS (m / z): 879.5 [M+H] + ; LC-MS retention time RT = 1.68 min. HPLC retention time retention time RT = 12.78 min.
[0141] 1H NMR (500MHz, DMSO-d6) δ9.25(d,J=2.1Hz,1H),8.52(t,J=4.3Hz,2H),8.26(d,J=2.2Hz,1H),7.82(s,1H),7.77(dd,J=8.6,1.5Hz,1H),7.60( d,J=8.7Hz,1H),7.22(s,1H),5.56(t,J=9.3Hz,1H),5.10–5.05(m,1H) ,4.39–4.32(m,2H),4.28–4.08(m,4H),3.76(s,2H),3.62–3.57(m,6H) ,3.29(s,3H),3.19–3.10(m,2H),3.02–2.97(m,1H),2.78–2.72(m,1H),2.48(d,J=4.1Hz,3H),2.08(t,J=5.0Hz,1H),1.83–1.76(m,2H),1.5 4–1.47(m,2H),1.40(d,J=6.1Hz,3H),1.27–1.23(m,1H),1.16–1.10(m ,1H),1.07(s,3H),0.92–0.85(m,7H),0.58–0.53(m,1H),0.36(s,3H).
[0142] Compound 1'
[0143] ESI-MS (m / z): 879.5 [M+H] + LC-MS retention time RT = 1.65 min. HPLC retention time Retention time RT = 12.59 min.
[0144] 1H NMR(500MHz,DMSO-d6)δ9.26(d,J=2.1Hz,1H),8.53(d,J=9.0Hz,2H),8.40(d,J= 2.2Hz,1H),7.82(s,1H),7.75(dd,J=8.7,1.5Hz,1H),7.56(d,J=8.7Hz,1H),7.17 (s,1H),5.55(t,J=9.4Hz,1H),5.10–5.05(m,1H),4.27–4.21(m,2H),4.07–4.02 (m,1H),4.02–3.95(m,1H),3.89–3.82(m,1H),3.76(s,2H),3.67(d,J=10.8Hz,1H ),3.63–3.54(m,6H),3.18–3.14(m,1H),3.12(s,3H),3.10–3.05(m,1H),2.80–2 .73(m,1H),2.49–2.47(m,3H),2.40–2.35(m,1H),2.15–2.10(m,1H),1.80(s,2H) ,1.55–1.47(m,2H),1.27(d,J=6.3Hz,3H),1.12(t,J=7.1Hz,3H),1.07(s,4H),0. 92(s,3H),0.88(dd,J=7.1,6.1Hz,2H),0.56(dd,J=7.6,5.4Hz,1H),0.49(s,3H).
[0145] Biological screening of RAS inhibitors and results
[0146] Test Example 1: In vitro cell proliferation inhibition test
[0147] Due to the diversity of RAS mutations and to evaluate the activity of compounds in cell lines with different RAS mutations, we selected KRAS WT 、KRAS G12C 、KRAS G12D 、KRAS G12V The in vitro activity of the compounds was evaluated and screened using the BRAF mutant cell lines (see table below).
[0148] Cell Line Histotype Mutant NCI-H358 Lung;Bronchiole KRAS(p.G12C) MIA PaCa-2 Pancreas KRAS(p.G12C) LS513 Large intestine;Cecum KRAS(p.G12D) AsPC-1 Pancreas KRAS(p.G12D) HCC1588 Lung KRAS(p.G12D);BRAF(p.E204L) SW480 Large intestine;Colon KRAS(p.G12V) NCI-H727 Lung;Bronchus KRAS(p.G12V) NCI-H520 Lung <![CDATA[KRAS WT ;]]> HT-29 Colon <![CDATA[KRAS WT ;BRAF(p.V600E)]]>
[0149] Experimental protocol: Cell Luminescent Viability Assay(Promega)
[0150] According to the doubling time of different cell lines, different numbers of cells (1000-5000 cells / well) were seeded in 96-well plates containing 180 μl of corresponding culture medium and incubated in an incubator containing 5% CO. 2 The cells were cultured overnight in a 37°C cell culture incubator. The next day, the compound to be tested was pre-diluted 3-fold with culture medium, with the highest concentration being 100 μM, for a total of 10 concentration gradients; then 20 μl of culture medium containing different concentrations of the compound was added to the cells in the 96-well plate to ensure that the final concentration of the compound was up to 10 μM, with 10 concentration gradients of 3-fold dilution. After the cells and compounds were co-incubated for 72 hours, the 96-well plate was removed from the incubator and equilibrated at room temperature for 30 minutes, and then 25 μl of Reagent was thoroughly mixed and incubated at room temperature for 10 min, after which 100 μl of sample was transferred to a white 96-well plate (OptiPlate TM -96, PerkinElmer) and using a multifunctional microplate reader ( i3x, Molecular devices) to read the fluorescence signal value. The signal value was then standardized, and the curve was fitted using a four-parameter fitting regression equation to calculate the half maximal inhibitory concentration (IC50) of the compound on the cell line.
[0151] Table 3: Antiproliferative activity of the compounds of the present invention against KRAS mutant cell lines
[0152]
Claims
1. A compound having the following structure:
2. The compound according to claim 1, which is prepared by the following steps: Step 1: Dissolve intermediate INT-2 and intermediate INT-6 in a mixed solvent of 1,4-dioxane and water, add [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride and potassium phosphate; replace nitrogen in the reaction system and heat, cool the reaction solution, filter the reaction solution, concentrate the filtrate, and separate and purify the residue to obtain compound 1a; Step 2: Compound 1a is dissolved in N,N-dimethylformamide, cesium carbonate is added, and then ethyl iodide is added dropwise to the reaction solution, and the reaction solution is stirred at room temperature until the reaction is completed; the reaction system is extracted, washed, dried, filtered and concentrated to obtain compound 1b; Step 3: The crude product of the above compound 1b was dissolved in dichloromethane, and trifluoroacetic acid was added dropwise to the reaction solution at 0°C; after the reaction was completed, the reaction solution was quenched with a saturated sodium bicarbonate aqueous solution, and after extraction and separation, the organic phase was dried, filtered and concentrated to obtain compound 1c; Step 4: Dissolve the above compound 1c and intermediate INT-3 in N,N-dimethylformamide, add N,N-diisopropylethylamine and (2-hydroxy-cyanoacetic acid ethyl)-N,N-dimethyl-morpholinoura hexafluorophosphate, and stir the reaction solution at 0°C. After the reaction is completed, the reaction system is extracted, washed, dried, filtered and concentrated, and the residue is separated and purified to obtain white solid compound 1 and diastereoisomer compound 1'.
Citation Information
Patent Citations
Pan-KRAS inhibitor compound
CN118047799A
Ras inhibitors
US20220105185A1
Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
WO2022060583A1
Methods for inhibiting ras
WO2022212894A1
Use of SOS1 inhibitors with ras inhibitors to treat cancers
WO2022217053A1
Cited By
Pan-KRAS inhibitor compound
CN118047799A
